News
Press Releases
2018/12/13
WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange
HONG KONG and SHANGHAI, December 13, 2018-- WuXi AppTec Co., Ltd. (“WuXi AppTec” or “the Company”; Stock code: 603259.SH/2359.HK) today announced the listing of approximately 116 million H-shares on the Main Board of the Hong Kong Stock Exchange. Based on the offer price of HK$68 per share, the net proceeds to be received by the Company are about HK$7,553 million (assuming the Over-allotment Option is not exercised).
Read more2018/12/11
WuXi AppTec Expands Site in California for Pharmaceutical R&D Services
SAN DIEGO, CA and SHANGHAI, December 11, 2018 – WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces the expansion of its facilities in San Diego, California.
Read more2018/11/28
WuXi AppTec Receives 2018 Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award from Frost & Sullivan
SHANGHAI, Nov. 28, 2018 -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it received the 2018 Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award from Frost & Sullivan, a top-notch business research and consulting firm. WuXi was awarded for the second consecutive year.
Read more2018/11/16
WuXi AppTec Opens Its New Medical Device Testing Center in Suzhou
WuXi AppTec announces today that its Laboratory Testing Division’s new Medical Device Testing Center opens today in Suzhou, China.
Read more2018/09/06
WuXi AppTec Partner Hutchison MediPharma Receives Approval of Fruquintinib Capsules in China
SHANGHAI, Sep 6, 2018: WuXi AppTec congratulates its partner Hutchison MediPharma (HMP) on receiving approval of fruquintinib capsules (Elunate®) for metastatic colorectal cancer from the National Medical Products Administration of China (“NMPA”) – formerly the China Food and Drug Administration. Fruquintinib is an innovative medicine that has not previously been launched in China or internationally.
Read more